NorthWest Biotherapeutics Inc (NWBO)

[Poor Man -]

A partnership is actually the next logical step to fund the company and set the conditions for a listing. A scientific journal article has no effect in and of itself to holding the ASM. I’m sure they must know a JA won’t hold much water with shareholders as the only rationale to increase the number of authorized shares. Imagine what that ugly scenario would look like!

Partnerships happen at all stages in the drug development cycle, and often include milestone payments. There’s no need to necessarily wait until an approval in the UK. If they were to wait, it would just mean more and substantial dilution — which they likely want to avoid.

Unless the MHRA is imminent, I just can’t see them putting the plane into a nose dive before entering into a JV or partnership of some sorts.